Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
Current Signal: SELL (auto-tracking)
-2.29% $46.52
America/New_York / 19 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 3 397.14 mill |
EPS: | 0.0500 |
P/E: | 930.40 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 73.03 mill |
Avg Daily Volume: | 0.559 mill |
RATING 2024-04-19 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Strong Buy | |
P/E: | Strong Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 930.40 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
49.72x |
Company: PE 930.40 | industry: PE 18.71 |
DISCOUNTED CASH FLOW VALUE |
---|
$-17.19 (-136.95%) $-63.71 |
Date: 2024-04-20 |
Expected Trading Range (DAY) |
---|
$ 44.80 - 48.24 ( +/- 3.69%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-01 | Stolper Mark | Buy | 14 072 | Common Stock |
2024-03-01 | Stolper Mark | Buy | 27 276 | Employee Stock Option (right to buy) |
2024-03-01 | Patel Mital | Buy | 15 422 | Common Stock |
2024-03-01 | Patel Mital | Buy | 29 891 | Employee Stock Option (right to buy) |
2024-03-01 | Katz David Jeffrey | Buy | 15 422 | Common Stock |
INSIDER POWER |
---|
73.90 |
Last 99 transactions |
Buy: 1 387 551 | Sell: 227 567 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $46.52 (-2.29% ) |
Volume | 0.594 mill |
Avg. Vol. | 0.559 mill |
% of Avg. Vol | 106.44 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:31 | sell | $35.70 | N/A | Active |
---|
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of images in the field of mammography, as well as AI solutions for lung and prostate cancer. As of December 31, 2021, it owned and managed 347 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.